|
|||||
|
|
Thyroid carcinoma after treatment for malignancies in childhood and adolescence: from diagnosis through follow-up |
|
| Authors: | Podda Marta Giorgia Terenziani Monica Gandola Lorenza Collini Paola Pizzi Natalia Marchianò Alfonso Morosi Carlo Luksch Roberto Ferrari Andrea Casanova Michela Spreafico Filippo Polastri Daniela Meazza Cristina Catania Serena Schiavello Elisabetta Biassoni Veronica Massimino Maura |
| Institution: | 1. Unit of Medical Oncology, Department of Onco-Hematology, IRCCS, Centro di Riferimento Oncologico della Basilicata, I.R.C.C.S., Via Padre Pio 1, 85028, Rionero in Vulture, PZ, Italy 2. Hospital Pharmacy, IRCCS Centro di Riferimento Oncologico della Basilicata, Rionero in Vulture, PZ, Italy 3. Department of Oncology, San Raffaele Scientific Institute, Milan, Italy |
| Abstract: | Non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations derive greater benefits from first- and second-generation tyrosine kinase inhibitors (TKIs) than from chemotherapy, especially in the first-line setting. Thus, main treatment guidelines indicate to test all patients with lung adenocarcinoma for these genetic abnormalities and recommend the employment of TKIs in these patients. However, many unanswered questions about the optimal use of TKIs in lung cancer remain; in particular, an open question is which of the currently available TKIs (gefitinib, erlotinib and afatinib) might be the best choice in untreated NSCLC patients. In the current review, we will analyze the state of EGFR-TKIs therapy in untreated EGFR-mutated NSCLC patients with a focus on both efficacy and toxicity. |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ | |